Seeking Direction: How to Manage Device Patients at the End of Life

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon
cover_1334773451.jpg - Device management

Nearly 20 percent of patients with implantable cardioverter-defibrillators (ICDs) receive painful shocks near the end of life, leaving physicians to question how to care for patients in these trying times (Pacing Clin Electrophysiol 2000;23[6]:934-938). When to initiate end-of-life discussions, as well as the legal and ethical ramifications of withdrawing a device in a terminally ill device patient, are challenging considerations for physicians and administrators. 

Reaching a consensus

More than 100,000 patients in the U.S. undergo cardiovascular implantable electronic device (CIED) procedures each year. Because pacemakers, ICDs and cardiac resynchronization therapy (CRT) are deemed life-sustaining therapies and often are depicted as a form of life support, some physicians feel uncomfortable withdrawing device therapy, even when they painfully shock patients at the end of their lives. Others have questioned the legality of deactivating CIEDs at the end of life.

At HRS.10, Rachel J. Lampert, MD, associate professor of medicine at the Yale School of Medicine in New Haven, Conn., and other key players created a consensus statement to help address such questions for the electrophysiology community. The document has become a go-to resource guide for providers looking for recommendations on how to manage device patients properly, particularly those near the end of life. For instance, the Heart Rhythm Society (HRS) concluded that withdrawing unwanted therapies, like CIEDs, is not hastening death, but instead is alleviating the burden of the device. Therefore, ethically, the patient should have the right to such deactivation.

“Informed consent is the most important legal doctrine in the clinician-patient relationship,” Lampert et al wrote. “Clinicians are ethically and legally obligated to ensure that patients are informed and allowed to participate in decision making regarding their diagnoses and treatment options.” Patients have the right to refuse treatment that was previously consented if it no longer meets their treatment goals and wishes, the statement outlined. “Honoring these decisions is an integral part of patient-centered care.”

The Supreme Court has affirmed the rights of patients or their surrogates to discontinue life-sustaining interventions, Lampert notes, including device therapy. “It is not specific procedures that have rights,” Lampert says. “It is patients.”

Have the conversation

CIEDs can help tack on years to a patient’s life, says William R. Lewis, MD, chief of clinical cardiology at MetroHealth Medical Center Heart and Vascular Center in Cleveland. Therefore, as device patients age, they may be more apt to acquire other life-threatening diseases such as cancer that are independent of the CIED. These considerations could make the issue of device deactivation a real concern at some point.  

Often, due to failing health, device patients are shocked near the end of their lives and want their devices turned off immediately. “This becomes a very difficult situation for caregivers, because at that point, the end is near and a device patient may be in too much pain to hear conversations about device deactivation,” says Lewis.

Nathan E. Goldstein, MD, associate professor of geriatrics and palliative medicine at the Mount Sinai School of Medicine in New York City, says there are three key elements emerging from literature:

  • Device patients are being shocked near the end of life;
  • Physicians and patients rarely talk about this issue; and
  • Patients who are on hospice are being shocked by devices.

When Goldstein and colleagues assessed how 414 hospice care centers handled ICD patients at the end of life, they found that only 10 percent of respondents said that they had a policy in place to discuss device deactivation with these patients (Ann Intern Med 2010;152[5]:296-299). However, 58 percent of survey respondents said that an ICD patient had received a shock within the past year.

“We in the field in medicine should be doing a better job of letting device patients know that device deactivation is really something to think about,” says Goldstein.

The first piece of the puzzle is getting the patient on board and allowing him or her to understand the functions of the CIED, especially the fact that they may result in shock or pain, says Lewis. That begins with a patient-physician tête-à-tête about risks and benefits. But the literature shows that these conversations are few and far between in practice.